We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Call failed

5 Aug 2020 By Robert Cyran

Teladoc and Livongo are riding a pandemic-driven telemedicine high. Teladoc hopes buying its rival will unleash even more revenue. The fall in both companies’ inflated stock prices suggests investors are questioning the need for M&A if the firms’ individual futures are so bright.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)